겨드랑이 다한증 : 시장 인사이트, 역학 및 시장 예측(2036년)

Axillary Hyperhidrosis Insights and Trends

• Axillary hyperhidrosis is a form of primary focal hyperhidrosis characterized by excessive sweating of the underarms (armpits) not related to heat or exercise.
• Axillary hyperhidrosis is the most prevalent subtype of primary focal hyperhidrosis, often serving as the initial and most disruptive presentation due to its visible impact on daily life, clothing, and social interactions.
• A wide range of nonsurgical (e.g., topical, systemic) and surgical treatments are available for patients with axillary hyperhidrosis. Treatment options for axillary hyperhidrosis are Aluminum chloride, Sofironium, Anticholinergics, Microwave Therapy, Radiofrequency Therapy, Endoscopic Thoracic Sympathectomy, Liposuction and Excision, Photodynamic therapy, lasers, and others.
• Drugs approved for the treatment of axillary hyperhidrosis include QBREXZA (Journey Medical Corporation), BRELLA (Candesant Biomedical), SOFDRA (Botanix Pharmaceuticals), and others.
• Surgical management of axillary hyperhidrosis includes local procedures such as excision, curettage, liposuction, laser therapy, or combination approaches to remove or destroy sweat glands under local anesthesia in outpatient settings. These techniques generally demonstrate favorable outcomes with lower risk profiles, whereas endoscopic thoracic sympathectomy (ETS) is typically not recommended for isolated underarm sweating due to higher procedural risks and less predictable outcomes.
• Despite the availability of several FDA-approved therapies for Axillary hyperhidrosis, the emerging development pipeline remains limited.

DelveInsight's 'Axillary Hyperhidrosis - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Axillary Hyperhidrosis, historical and forecasted epidemiology, as well as the Axillary Hyperhidrosis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Axillary Hyperhidrosis market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Axillary Hyperhidrosis patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Axillary Hyperhidrosis and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Axillary Hyperhidrosis Market

Axillary Hyperhidrosis as a Chronic Long-Term Condition

Axillary hyperhidrosis is increasingly recognized as a chronic, persistent disorder rather than a transient condition, with symptoms often lasting for years and significantly impairing daily functioning, psychosocial well-being, and quality of life without sustained remission.

Axillary Hyperhidrosis as a Sympathetic Hyperactivity Disorder

Axillary hyperhidrosis is increasingly characterized as a disorder of sympathetic nervous system hyperactivity, involving excessive stimulation of eccrine sweat glands despite normal gland structure. The condition is associated with dysregulation of autonomic signaling pathways, heightened cholinergic activity, and exaggerated sweat responses to emotional or thermal triggers.

Axillary Hyperhidrosis Understanding and Treatment Algorithm

Axillary Hyperhidrosis Overview and Diagnosis

Axillary hyperhidrosis is a chronic condition characterized by excessive, uncontrollable sweating of the underarms, beyond what is necessary for thermoregulation. It is the most common subtype of primary focal hyperhidrosis, often beginning in adolescence or early adulthood. The condition typically occurs symmetrically in both armpits and is not triggered by heat or exercise, but rather by emotional or unknown stimuli. It significantly impacts quality of life, leading to social embarrassment, occupational difficulties, and emotional distress.

Axillary hyperhidrosis is diagnosed clinically, based on persistent, excessive underarm sweating without an identifiable cause, typically present for over six months. Key features include bilateral, symmetrical sweating that impairs daily life, often beginning before age 25 and stopping during sleep. The Hyperhidrosis Disease Severity Scale (HDSS) helps assess symptom impact. In unclear cases, tests like the starch-iodine test or gravimetric measurement can confirm severity. Secondary causes-such as hyperthyroidism, diabetes, or neurological disorders should be ruled out if sweating is generalized, asymmetric, or occurs during sleep or later in life.

Axillary Hyperhidrosis Treatment

First-line treatment includes aluminum chloride hexahydrate (e.g., DRYSOL), applied nightly to block sweat glands. If ineffective, FDA-approved topical anticholinergics like QBREXZA (wipes) and SOFDRA (gel) are used. For more widespread cases, oral anticholinergics such as OXYBUTYNIN or GLYCOPYRROLATE may help but can cause side effects. BOTOX injections offer 4-14 months of relief by blocking nerve signals to sweat glands. Other options include MIRADRY (microwave therapy), BRELLA (a quick office patch), and laser treatments. In severe cases, endoscopic thoracic sympathectomy (ETS) may be considered, though it carries significant risks and is used as a last resort.

Axillary Hyperhidrosis Unmet Needs

The section "unmet needs of Axillary Hyperhidrosis" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Limited long-term disease control with frequent symptom recurrence

2. High treatment burden due to repeated procedures, maintenance therapy, and variable durability of response

3. Persistent psychosocial and quality-of-life impairment, including anxiety, social embarrassment, and occupational limitations, and others.....

Comprehensive unmet needs insights in Axillary Hyperhidrosis and their strategic implications are provided in the full report.

Axillary Hyperhidrosis Epidemiology

Key Findings from Axillary Hyperhidrosis Epidemiological Analysis and Forecast

• Axillary hyperhidrosis affects 51% of patients, either as an isolated condition or in combination with sweating in other areas, with 9.5% experiencing axillary sweating alone. Palmar hyperhidrosis is seen in 25% of cases, also as isolated or combined involvement, but only 1% of patients have palmar hyperhidrosis as the sole affected area.
• In the UK, hyperhidrosis is considered common by the NHS, with estimates suggesting it affects between 1% and 3% of the population.
• Primary hyperhidrosis is not solely dictated by the season, with 65% of patients reporting that their sweating bothers them equally throughout the year.
• The prevalence of healthcare-seeking behavior for hyperhidrosis was higher among women (47.5%) compared to men (28.6%).
• In Germany, axillary hyperhidrosis has a notably high prevalence, affecting approximately 16% of the population.

Axillary Hyperhidrosis Drug Chapters & Competitive Analysis

The Axillary Hyperhidrosis drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Axillary hyperhidrosis treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Axillary hyperhidrosis therapeutics market.

Approved Therapies for Axillary Hyperhidrosis

SOFDRA: Botanix Pharmaceuticals

In June 2024, SOFDRA received approval from the FDA for the treatment of primary axillary hyperhidrosis in adults and children aged 9 years and older. SOFDRA is a topical prescription gel that differs from traditional antiperspirants by working through a distinct mechanism and containing no aluminum. Its active ingredient, sofpironium (12.45%), is an anticholinergic agent that blocks nerve signals to the sweat glands, preventing their activation. Applied directly to the underarms, SOFDRA targets sweating at the source with limited systemic absorption. Its novel chemical structure distinguishes it from oral anticholinergics, which often cause side effects such as dry mouth, muscle cramps, or urinary retention. By acting locally, SOFDRA minimizes the risk of systemic side effects, though it must be used as directed and should not be combined with other anticholinergic products to avoid potential adverse effects.

QBREXZA: Journey Medical Corporation

QBREXZA (glycopyrronium tosylate) is a prescription topical anticholinergic approved for the treatment of primary axillary hyperhidrosis in patients aged 9 and older. It is applied once daily using a pre-moistened cloth to clean and dry underarms, where it works by blocking nerve signals that activate sweat glands. This targeted mechanism provides a localized, non-invasive alternative to traditional antiperspirants, offering significant relief for individuals whose underarm sweating interferes with daily functioning, social confidence, and emotional well-being. While generally well-tolerated, potential side effects include dry mouth, blurred vision, and skin irritation, and it should be avoided in individuals with conditions contraindicated for anticholinergic use.

Axillary Hyperhidrosis Key Players and Market Leaders

• Botanix Pharmaceuticals
• Journey Medical Corporation, and others

Axillary Hyperhidrosis Market Outlook

Hyperhidrosis, affecting approximately 2.8% of the US population, remains an under-recognized condition with a significant impact on quality of life and limited treatment options. Despite its prevalence and burden, there are no FDA-approved disease-modifying therapies, highlighting a clear unmet medical need. Current treatments, ranging from topical agents and oral medications to procedures like botulinum toxin injections and microwave therapy, often offer only temporary relief and are limited by side effects or recurrence. With few companies actively developing targeted therapies, there is a substantial opportunity for innovation in this space. Advancing safe, effective, and durable treatments that address the underlying mechanisms of hyperhidrosis could significantly improve patient outcomes and fill a critical therapeutic gap.

Drug Class/Insights into Leading Marketed Therapies in Axillary Hyperhidrosis (2022-2036 Forecast)

SOFDRA belongs to the topical anticholinergic class and represents a targeted approach for treating axillary hyperhidrosis by modulating overactive cholinergic signaling in eccrine sweat glands. Unlike systemic therapies that may broadly affect autonomic activity, SOFDRA selectively inhibits acetylcholine-mediated sweat stimulation locally at the application site. This mechanism reduces excessive sweat production while limiting systemic exposure. As a result, SOFDRA offers effective improvement in underarm sweating with a noninvasive administration route and potentially lower risk of systemic adverse effects compared with oral anticholinergic therapies.

Axillary Hyperhidrosis Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the Axillary Hyperhidrosis market's uptake by drugs, patient uptake by therapy, and sales of each drug.

Axillary Hyperhidrosis Therapies Price Scenario & Trends

Pricing and analogue assessment of Axillary hyperhidrosis therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report....

Industry Experts and Physician Views for Axillary Hyperhidrosis

To keep up with axillary hyperhidrosis market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the axillary hyperhidrosis emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in axillary hyperhidrosis, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the Harvard Medical School, Boston Children's Hospital, University of South Carolina, and Duke University, etc. were contacted. Their opinion helps understand and validate current and emerging axillary hyperhidrosis therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in axillary hyperhidrosis.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of axillary hyperhidrosis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of axillary hyperhidrosis, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the axillary hyperhidrosis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM axillary hyperhidrosis market.

Report Insights

• Axillary Hyperhidrosis Patient Population Forecast
• Axillary Hyperhidrosis Therapeutics Market Size
• Axillary Hyperhidrosis Pipeline Analysis
• Axillary Hyperhidrosis Market Size and Trends
• Axillary Hyperhidrosis Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year Forecast
• Axillary Hyperhidrosis Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Axillary Hyperhidrosis Treatment Addressable Market (TAM)
• Axillary Hyperhidrosis Competitive Landscape
• Axillary Hyperhidrosis Major Companies Insights
• Axillary Hyperhidrosis Price Trends and Analogue Assessment
• Axillary Hyperhidrosis Therapies Drug Adoption/Uptake
• Axillary Hyperhidrosis Therapies Peak Patient Share Analysis

Report Assessment

• Axillary Hyperhidrosis Current Treatment Practices
• Axillary Hyperhidrosis Unmet Needs
• Axillary Hyperhidrosis Clinical Development Analysis
• Axillary Hyperhidrosis Emerging Drugs Product Profiles
• Axillary Hyperhidrosis Market Attractiveness
• Axillary Hyperhidrosis Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the axillary hyperhidrosis market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of axillary hyperhidrosis?
• What are the disease risks, burdens, and unmet needs of axillary hyperhidrosis? What will be the growth opportunities across the 7MM concerning the patient population with axillary hyperhidrosis?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of axillary hyperhidrosis? What are the current guidelines for treating axillary hyperhidrosis in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the axillary hyperhidrosis market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalyst
• 4.2. Key Transactions and Collaboration
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology

6. Axillary Hyperhidrosis Market Overview at a Glance

• 6.1. Market Share (%) Distribution of Axillary Hyperhidrosis in 2025
• 6.2. Market Share (%) Distribution of Axillary Hyperhidrosis in 2036

7. Disease Background and Overview: Axillary hyperhidrosis

• 7.1. Introduction
• 7.2. Causes
• 7.3. Pathophysiology
• 7.4. Symptoms
• 7.5. Risk Factor
• 7.6. Diagnosis

8. Treatment and Management

• 8.1. Treatment Guidelines

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total Prevalent Cases of Axillary hyperhidrosis in the 7MM
• 9.4. United States
  • 9.4.1. Total Diagnosed Prevalent Cases of Axillary hyperhidrosis in the United states
  • 9.4.2. Type-specific Cases of Axillary hyperhidrosis in the United states
  • 9.4.3. Age-specific Cases of Axillary hyperhidrosis in the United states
  • 9.4.4. Gender-specific Cases of Axillary hyperhidrosis in the United states
  • 9.4.5. Site-specific Cases of Axillary hyperhidrosis in the United states
• 9.5. EU4 and the UK
  • 9.5.1. Total Diagnosed Prevalent Cases of Axillary Hyperhidrosis in the EU4 and the UK
  • 9.5.2. Type-specific Cases of Axillary Hyperhidrosis in the EU4 and the UK
  • 9.5.3. Age-specific Cases of Axillary Hyperhidrosis in the EU4 and the UK
  • 9.5.4. Gender-specific Cases of Axillary Hyperhidrosis in the EU4 and the UK
  • 9.5.5. Site-specific Cases of Axillary Hyperhidrosis in the EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Diagnosed Prevalent Cases of Axillary Hyperhidrosis in Japan
  • 9.6.2. Type-specific Cases of Axillary Hyperhidrosis in Japan
  • 9.6.3. Age-specific Cases of Axillary Hyperhidrosis in Japan
  • 9.6.4. Gender-specific Cases of Axillary Hyperhidrosis in Japan
  • 9.6.5. Site-specific Cases of Axillary Hyperhidrosis in Japan

10. Patient Journey

11. Marketed Drugs

• 11.1. Competitive Landscape: Marketed
• 11.2. SOFDRA: Botanix Pharmaceuticals
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Clinical Developmental Activities
  • 11.2.5. Safety and Efficacy
• 11.3. QBREXZA: Journey Medical Corporation
  • 11.3.1. Product Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Clinical Developmental Activities
  • 11.3.5. Safety and Efficacy

12. Axillary hyperhidrosis: Market Size

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebates
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptake
• 12.5. Total Axillary Hyperhidrosis Market Analysis in the 7MM
• 12.6. United States
  • 12.6.1. Total Market Size of Axillary Hyperhidrosis in the United States
  • 12.6.2. Market Size of Axillary Hyperhidrosis by Therapies in the United States
• 12.7. EU4 and the UK
  • 12.7.1. Total Market Size of Axillary Hyperhidrosis in EU4 and the UK
  • 12.7.2. Market Size of Axillary Hyperhidrosis by Therapies in EU4 and the UK
• 12.8. Japan
  • 12.8.1. Total Market Size of Axillary Hyperhidrosis in Japan
  • 12.8.2. Market Size of Axillary Hyperhidrosis by Therapies in Japan

13. Unmet Needs

14. SWOT Analysis

15. KOL Views

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW
• 16.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight